HCPCS Code J0275: Alprostadil urethral suppository billing guide

Key takeaways

HCPCS Code J0275 describes alprostadil urethral suppository, the intraurethral MUSE pellet prescribed to treat erectile dysfunction.

Viatris discontinued every MUSE presentation in the US in June 2024, and no generic replacement reached the market.

The official J0275 descriptor carries no dosage qualifier. You report one unit for each suppository supplied or administered, whatever its strength.

There is no 125 mcg billing unit for J0275. The per-1.25-mcg math belongs to J0270, the injection form, and applying it here inflates the units billed.

J0275 is generally excluded from Medicare Part B coverage under the self-administered drug (SAD) exclusion, per CMS Article A53066. Institutional exceptions may apply depending on your MAC.

Every claim needs an N52.x ICD-10-CM diagnosis code to establish medical necessity for erectile dysfunction.

HCPCS Code J0275 is the Level II code for alprostadil urethral suppository, the intraurethral pellet sold as MUSE for erectile dysfunction. The descriptor carries no dosage qualifier. You report one unit for each suppository supplied or administered, whatever its strength.

Two details decide whether a J0275 claim survives. Medicare Part B treats the drug as self-administered and generally excludes it. And the per-mcg unit math that applies to J0270 does not apply here.

This reference covers the descriptor, units of service, and Medicare coverage criteria. It also walks through 2026 fee schedule context, step-by-step billing requirements, current MUSE availability, and how J0275 differs from J0270.

J0275 definition and code attributes

HCPCS Code J0275 is a Level II Healthcare Common Procedure Coding System code maintained by the Centers for Medicare and Medicaid Services (CMS).

It represents alprostadil urethral suppository, delivered by the intraurethral route. The strength of the pellet never changes the code you report. Billers at a men’s health practice need the descriptor and the coverage limits in hand before submitting.

The J-code classification places J0275 among drugs administered other than by the oral method. Alprostadil urethral suppository is designed for the patient to insert at home. CMS therefore designates it a self-administered drug in most contexts, which carries the coverage consequences covered next.

Alprostadil urethral suppository: Drug and availability status

Alprostadil is a synthetic prostaglandin E1 (PGE1) that relaxes smooth muscle and increases blood flow. For erectile dysfunction (ED) it has two distinct delivery forms, each with its own HCPCS code. J0275 covers the urethral suppository route, sold as MUSE (Medicated Urethral System for Erection).

A practice running sexual health services alongside urology should record which form was dispensed.

MUSE pellets are inserted into the urethra, where alprostadil crosses the urethral mucosa and diffuses into erectile tissue. The FDA product label lists strengths of 125 mcg, 250 mcg, 500 mcg, and 1000 mcg. None of those numbers feed a unit calculation. A single 500 mcg pellet is one unit of service, not four.

MUSE itself is no longer on the US market. Viatris discontinued every MUSE presentation in June 2024, and no generic alprostadil urethral suppository replaced it.

J0275 remains active in the HCPCS file, so the code still has work to do. It applies to legacy stock dispensed before supplies ran out, to a compounded intraurethral product, and to historical claims still under appeal or audit. For a new prescription, the injectable forms behind J0270 are the practical route.

Recording the strength and the quantity dispensed at the point of prescribing keeps the unit count defensible. A prescription management record ties the dispensed quantity to the claim, so nobody rebuilds it from memory later.

Primary indication and ICD-10 linkage

J0275 is indicated specifically for erectile dysfunction. The ICD-10-CM N52 family (male erectile dysfunction) is the required diagnosis category for medical necessity.

A claim submitted without an N52.x code in the primary diagnosis field is likely to be denied, whatever the payer.

Medicare coverage and the self-administered drug exclusion

Under CMS Article A53066, alprostadil urethral suppository is listed as a self-administered drug (SAD). Medicare Part B generally does not cover drugs a patient can self-administer, because Part B is built for drugs that need clinical administration.

MUSE was intended for home use without clinician involvement, so it falls outside standard Part B coverage in most circumstances.

What the SAD exclusion means for your claims

The exclusion is not absolute. Medicare Administrative Contractors (MACs) can grant exceptions for patients in institutional settings, such as hospital outpatient departments or skilled nursing facilities.

Those exceptions cover cases where the drug cannot practically be self-administered. They are narrow, and they require specific documentation.

Before sending any J0275 claim to Medicare Part B, billing staff should:

• Confirm whether the treating MAC has a Local Coverage Determination (LCD) or local policy on suppository exceptions
• Verify that the place of service code reflects a clinical setting rather than home use
• Document why in-office administration was clinically necessary
• Cite CMS Article A53066 and the applicable exception criteria in any denial appeal

For most outpatient urology practices, J0275 will not be reimbursable under Medicare Part B. Private payers and Medicaid work under separate rules. Medicaid coverage varies significantly by state, so check state formulary inclusion before billing rather than assuming it applies.

Required ICD-10 diagnosis codes

J0275 may be billable to a private payer, to Medicaid where it is covered, or under a qualifying MAC exception. In each case the claim must carry a diagnosis code from the N52 series. The most commonly used codes are below. Verify them against the relevant MAC LCD or payer policy first, because covered diagnosis lists vary.

Fee schedule and reimbursement context for 2026

J0275 is almost always excluded from Medicare Part B under the SAD exclusion. The data below therefore matters most for private payer negotiations, covered Medicaid programs, and the narrow institutional exceptions above.

Medicare Part B pricing for J0275 is based on the Average Sales Price (ASP) methodology. Confirm the applicable pricing indicator in the current CMS HCPCS file, because methodology varies by code status.

The CMS Physician Fee Schedule carries verified 2026 allowable amounts by MAC jurisdiction.

All rate figures are reference estimates only. Actual reimbursement depends on the payer contract, geographic location, MAC jurisdiction, and plan year. Never present a fee schedule estimate to a patient as a guaranteed payment amount.

How to bill J0275 step by step

Even where Medicare does not cover J0275, correct claim preparation still matters for private payers, Medicaid, and exception scenarios. A claims management workflow catches submission errors before the claim leaves the practice.

1. Confirm payer coverage first. Before prescribing and dispensing, verify whether the patient’s payer covers J0275. For Medicare, check the applicable MAC’s LCD or coverage article. For Medicaid, check the state formulary. For commercial plans, confirm formulary inclusion and prior authorization rules.
2. Document medical necessity. The clinical record must support erectile dysfunction with an appropriate N52.x ICD-10-CM diagnosis. Record the clinical evaluation, any failed prior therapies, and the rationale for choosing alprostadil over an oral agent.
3. Determine units of service. Report one unit for each suppository supplied or administered. There is no per-mcg unit of measure to divide by. A 500 mcg pellet is one unit, and a six-pellet carton billed on one line is six units. Confirm the quantity convention with the payer, since some plans want the supply split across dates of service.
4. Select the correct place of service. For a Medicare exception claim, the place of service must reflect clinical administration in a facility setting. Retail or home-based dispensing does not qualify. For commercial payers, follow the plan’s own place of service rules.
5. Attach the diagnosis code. Link the primary N52.x ICD-10-CM code to J0275 on the claim. List contributing conditions such as diabetes or post-prostatectomy status as secondary diagnoses.
6. Submit with required modifiers. Check whether the MAC or the commercial payer requires specific modifiers for drug J-codes in your setting. Modifier requirements vary by payer and place of service.
7. Retain documentation for audit. Keep the prescription, the dispensing record, the clinical notes, and any prior authorization paperwork. J-code claims for ED drugs carry elevated audit risk, particularly under Medicare.

Documentation requirements for every claim

J0275 sits in a category payers audit closely, so the record has to stand on its own without a phone call. Keep the following in the chart for every claim:

• The prescription or order, naming the product and the strength dispensed
• The dispensing record, showing how many suppositories were supplied and on what date
• An N52.x ICD-10-CM diagnosis supported by the clinical evaluation in the note
• The rationale for alprostadil over an oral agent, including any failed prior therapy
• Prior authorization reference numbers, with the approved quantity and date range
• For any Medicare exception claim, the reason self-administration was not feasible

J0275 vs J0270: Choosing the right alprostadil code

Alprostadil has two billing-distinct forms, and using the wrong code is a frequent source of rejection. The AAPC HCPCS lookup is a quick way to confirm the distinction during claim preparation.

Where the 125 mcg billing unit myth comes from

The per-mcg unit belongs to J0270, not J0275. J0270 reads Injection, alprostadil, 1.25 mcg, so its units really are calculated from the dose. Coding cheat sheets and internal billing macros then borrow that habit. They staple a 125 mcg unit onto J0275, because 125 mcg is the smallest MUSE strength.

No CMS file, MAC policy, or state Medicaid schedule defines a 125 mcg unit for J0275. The CMS Table of Drugs and the quarterly ASP payment limit files list the code without a dosage qualifier. The ASP payment limit is stated per unit of service.

Every J-code states its own unit basis in the descriptor, so read it code by code rather than by analogy. The billing reference for J0290 works through the unit rule for a different injectable drug. Some claim scrubbers and billing templates still multiply the mcg strength for J0275, and that inherited rule needs to come out.

Why J0278 is not a related alprostadil code

J0278 is not an alprostadil code. It describes an injection of amikacin sulfate, an aminoglycoside antibiotic with no connection to erectile dysfunction. Its only link to J0275 is a nearby position in the HCPCS J-code number range.

Coding platforms group numerically adjacent codes under headings like related codes, and billers read that as clinical kinship. For alprostadil the pair is J0270 and J0275, and nothing else belongs on that list. Codes such as J0745 and J2597 sit elsewhere in the J-code range with entirely different drugs behind them.

Confirm the descriptor and the active status in the current CMS HCPCS file before billing any code a reference tool suggests. Descriptors and coverage status both change with the annual update.

Common billing errors and compliance tips

J0275 claims fail more often than average, because the SAD exclusion, unit conventions borrowed from J0270, and diagnosis specificity all interact. HIPAA compliance is a baseline requirement, and J0275 needs a tighter pre-submission review than most J-codes. The errors below account for the bulk of denials in urology billing.

A practice with meaningful urology or men’s health claim volume should keep a J0275-specific documentation standard, separate from the general J-code workflow. The SAD exclusion risk, the borrowed unit convention, and the prior authorization frequency together make this one of the higher-maintenance codes in the category.

Structured digital intake forms for men’s health consultations help as well. They capture prior ED treatment history, current medications, and the clinical basis for choosing alprostadil. The medical necessity evidence is then already in the record before billing staff open the claim.

How Pabau keeps J0275 units and coverage checks aligned

Most J0275 write-offs start with information sitting in three places. The prescription is in the clinical note. The coverage check is in somebody’s inbox. The unit count gets rebuilt from memory when the claim is keyed.

Practice management software like Pabau keeps all of it on one patient record. The consultation form captures prior ED therapies and the clinical rationale. The prescription record holds the strength and the number of suppositories supplied. The unit count then comes from what was dispensed rather than a mcg calculation.

You can also stop a questionable claim before it leaves the practice. Flag every J0275 line for a coverage check, and attach the N52.x diagnosis while the note is still open. Keep the prescription, the note, and the authorization filed together in one patient record for audit.

Denials then surface in your own review queue rather than in a remittance advice six weeks later. Reporting shows which J-code lines keep coming back, so you can fix the rule instead of reworking the claim each time.

Manage J-code billing workflows without the compliance risk

Pabau helps urology and men's health practices track drug billing, flag missing diagnosis codes, and manage claim submissions without switching between multiple systems. See how it works for your practice.

Book a demo

Conclusion

The decision that matters with J0275 comes before the claim, not after it. Check the payer, count the suppositories, and attach the N52.x code while the note is still open. Do that and the SAD exclusion stops producing surprise write-offs.

The discontinuation also changes what this code is for. J0275 is now largely a legacy and appeals code, so treat a fresh claim as the exception that needs justifying. For a new ED prescription, J0270 is where the billing conversation starts.

Book a demo to see how Pabau ties prescription records, diagnosis codes, and claim submission together for urology and men’s health billing.

Continue your research

Working out how a per diem unit is reported? T1020 sets out the unit basis, coverage rules, and documentation a per diem code needs.

Need to get modifiers right on a HCPCS Level II claim? E0111 covers modifier selection, coverage criteria, and the documentation payers expect.

Building a documentation standard for a single code? G0268 shows what a code-specific billing, reimbursement, and documentation checklist looks like.

Restructuring the business side of a men’s health practice? MSOs in healthcare explains the model, its variations, and the compliance limits that apply.

Want fewer administrative errors across the practice? Patient care management covers how connected documentation and billing reduce mistakes in daily clinical work.

Frequently asked questions